Importantly, we found that patients with EGFR amplified recurrent GBMs (n = 110) treated with Depatux-M, either alone (Arm C) or in combination with TMZ (Arm B), had significantly more responders in patients with tumor volumes < 25 cm3 compared to those ≥25 cm3 at study entry (response rate of 17% vs 0%, P = .009 two-sided). This evidence concerns the gene EGFR and neoplasm.